Intravenous Haloperidol efficacy in improving conversion disorder patients in emergency

Intravenous Haloperidol against intravenous Diazepam in improving conversion disorder in the emergency room

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108317449N1

Enrollment

168

Registered

2012-06-23

Start date

2012-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

conversion disorder. Dissociative [conversion] disorders

Interventions

Intervention 1: Haloperidol, 5mg, Intravenous. Intervention 2: Diazepam, 5-10mg, Intravenous.

Treatment - Drugs

Haloperidol, 5mg, Intravenous

Diazepam, 5-10mg, Intravenous

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with conversion disorder according to DSM IV criteria referred to emergency room. Exclusion criteria: Patients with abnormal vital signs; ill; under 18; over 60; pregnant patients; opium addicted patients; Unwillingness to cooperation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The patient feel better. Timepoint: Before the intervention, one hour after the intervention and one week after intervention. Method of measurement: Standardized questionnaire, the patients feel better, better expressed by the patient and his companions.;The patient's symptoms disappear. Timepoint: Before the intervention, one hour after the intervention and one week after intervention. Method of measurement: Standardized questionnaire, the patients feel better, better expressed by the patient and his companions.	—

Measure

Time frame

The patient feel better. Timepoint: Before the intervention, one hour after the intervention and one week after intervention. Method of measurement: Standardized questionnaire, the patients feel better, better expressed by the patient and his companions.;The patient's symptoms disappear. Timepoint: Before the intervention, one hour after the intervention and one week after intervention. Method of measurement: Standardized questionnaire, the patients feel better, better expressed by the patient and his companions.

—

Secondary

Measure	Time frame
Drug side effects. Timepoint: Just after the intervention until a week later. Method of measurement: Questionaire, Physical exam.;Worsening of the patient. Timepoint: Just after the intervention until a week later. Method of measurement: Questionaire, Physical exam.;Treatment failure. Timepoint: Just after the intervention to one hour after the start of intervention. Method of measurement: Physical examination.	—

Measure

Time frame

Drug side effects. Timepoint: Just after the intervention until a week later. Method of measurement: Questionaire, Physical exam.;Worsening of the patient. Timepoint: Just after the intervention until a week later. Method of measurement: Questionaire, Physical exam.;Treatment failure. Timepoint: Just after the intervention to one hour after the start of intervention. Method of measurement: Physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Majid Shojaee

Shahid Beheshti Medical University

m.shojaee@sbmu.ac.ir+98 21 7343 2380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026